For the quantitative detection of Human mTOR
FRAP1 (mTOR) is a serine/threonine kinase that plays a critical role in cellular growth and proliferation. Perturbations in the mTOR/PI3-kinase/AKT pathway are associated with numerous forms of cancer. FRAP1 is also the target of rapamycin and its analogues, which are currently used as immunosuppressants and cancer therapeutics. Mutations affecting the gene results in Smith-Kingsmore syndrome.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-155230 |
| Réf. fabricant | 18057394 |
| Numéro d’adhésion | P42345 |
| Plage de dosage | 0.16 to 10 ng/mL |
| Sensibilité du dosage | 0.1 ng/mL |
| Conjugué | HRP |
| Type de produit | ELISA |
| Type d’échantillon | Plasma |
| À utiliser avec (équipement) | Colorimetric Microplate Reader |
| Identification génétique (Entrez) | 2475 |
| Symbole de gène(s) | MTOR |
| Coefficient de variation inter-dosage | <10% |
| Coefficient de variation intra-dosage | <10% |
| Contenus des kits | Pre-coated 96 well plate, Standard, Biotinylated Detection Antibody, HRP Conjugate, Standard & Sample Diluent, Biotinylated Detection Antibody Diluent, HRP Conjugate Diluent, Wash Buffer, TMB Substrate, Stop Solution, Plate Sealer |
| Marqueur ou colorant | HRP |
| Quantité | 96 Tests |
| État réglementaire | RUO |
| Volume d’échantillon | 100 µL |
| Conditions de stockage | Refer to product documentation for component specific storage temperature. |
| Cible | Human |
| Heure du test | 1 hr 20 min |
| Durée totale du dosage | 3 hr 30 min |
